Antonio Febbraro

2.9k total citations
56 papers, 1.2k citations indexed

About

Antonio Febbraro is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antonio Febbraro has authored 56 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 22 papers in Cancer Research and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antonio Febbraro's work include Cancer Treatment and Pharmacology (22 papers), Cancer Genomics and Diagnostics (15 papers) and Colorectal Cancer Treatments and Studies (15 papers). Antonio Febbraro is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Cancer Genomics and Diagnostics (15 papers) and Colorectal Cancer Treatments and Studies (15 papers). Antonio Febbraro collaborates with scholars based in Italy, Malaysia and Spain. Antonio Febbraro's co-authors include Massimo Pancione, Guido Giordano, Giovanni Ambrosino, F. Polistina, Paolo Francescon, Vittorio Colantuoni, Lina Sabatino, F. Casamassima, Andrea Remo and Pietro Parcesepe and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Antonio Febbraro

53 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Antonio Febbraro Italy	18	649	314	253	249	241	56	1.2k
Yun Liang China	21	459 0.7×	223 0.7×	433 1.7×	186 0.7×	121 0.5×	81	1.2k
Henrik Roed Denmark	22	755 1.2×	525 1.7×	308 1.2×	309 1.2×	119 0.5×	56	1.8k
Tyler P. Robin United States	17	608 0.9×	405 1.3×	272 1.1×	330 1.3×	198 0.8×	55	1.3k
Kim A. Reiss United States	19	971 1.5×	226 0.7×	147 0.6×	452 1.8×	444 1.8×	63	1.4k
Claudia Maggi Italy	21	873 1.3×	360 1.1×	259 1.0×	261 1.0×	301 1.2×	36	1.3k
Yasuo Ejima Japan	20	379 0.6×	394 1.3×	205 0.8×	332 1.3×	215 0.9×	49	1.3k
Kai Li China	23	1.2k 1.8×	675 2.1×	153 0.6×	477 1.9×	341 1.4×	95	1.8k
Jamie Lesnock United States	16	332 0.5×	107 0.3×	292 1.2×	186 0.7×	104 0.4×	52	1.2k
Andrew Gaya United Kingdom	17	410 0.6×	285 0.9×	204 0.8×	243 1.0×	150 0.6×	38	1.2k
Noh-Hyun Park South Korea	29	441 0.7×	327 1.0×	297 1.2×	398 1.6×	238 1.0×	77	2.1k

Countries citing papers authored by Antonio Febbraro

Since Specialization

Citations

This map shows the geographic impact of Antonio Febbraro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Febbraro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Febbraro more than expected).

Fields of papers citing papers by Antonio Febbraro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Febbraro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Febbraro. The network helps show where Antonio Febbraro may publish in the future.

Co-authorship network of co-authors of Antonio Febbraro

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Febbraro. A scholar is included among the top collaborators of Antonio Febbraro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Febbraro. Antonio Febbraro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orlando, Laura, Evaristo Maiello, Michele Orditura, et al.. (2024). Phase II randomized trial comparing metronomic anthracycline-containing chemotherapy versus standard schedule in untreated HER2 negative advanced breast cancer: activity and quality of life results of the GOIM 21003 trial. The Breast. 75. 103725–103725. 1 indexed citations

Soricelli, Andrea, et al.. (2024). Triple-Negative Breast Cancer EVs Modulate Growth and Migration of Normal Epithelial Lung Cells. International Journal of Molecular Sciences. 25(11). 5864–5864.

Prete, Salvatore Del, Liliana Montella, Grazia Arpino, et al.. (2020). Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. Oncotarget. 11(22). 2083–2091. 8 indexed citations

Orlando, Laura, Antonio Febbraro, Claudio Zamagni, et al.. (2019). Eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer patients: safety and efficacy. An Italian experience. Tumori Journal. 106(4). 301–305. 2 indexed citations

Giordano, Guido, Antonio Febbraro, Erica Quaquarini, et al.. (2018). Eribulin Treatment in Patients with Liver Metastatic Breast Cancer: Eight Italian Case Reports. Oncology. 94(Suppl. 1). 34–44. 1 indexed citations

Giordano, Guido, Antonio Febbraro, Michèle Milella, et al.. (2016). Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.. Journal of Clinical Oncology. 34(15_suppl). 4124–4124. 8 indexed citations

Orlando, Laura, Giovanna Giordano, Claudio Zamagni, et al.. (2016). Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience. Annals of Oncology. 27. vi76–vi76.

Maiello, Evaristo, Erika Martinelli, Claudia Cardone, et al.. (2016). Clinical activity of FOLFIRI plus cetuximab in elderly patients (pts) according to extended gene mutation status by Next Generation Sequencing (NGS) in the CAPRI- GOIM trial. Annals of Oncology. 27. iv39–iv39. 4 indexed citations

Giordano, Guido, Antonio Febbraro, Maria Lucia Sarnicola, et al.. (2015). Cancer-related CD15/FUT4 overexpression decreases benefit to agents targeting EGFR or VEGF acting as a novel RAF-MEK-ERK kinase downstream regulator in metastatic colorectal cancer. Journal of Experimental & Clinical Cancer Research. 34(1). 108–108. 57 indexed citations

10.

Rizzo, Mimma, Gaetano Facchini, Giuseppe Di Lorenzo, et al.. (2014). Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study. Future Oncology. 11(2). 219–224. 7 indexed citations

11.

Giordano, Guido, et al.. (2014). Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept. Gastroenterology Research and Practice. 2014. 1–13. 45 indexed citations

12.

Galetta, Domenico, Saverio Cinieri, Salvatore Pisconti, et al.. (2014). Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial. Clinical Lung Cancer. 16(4). 262–273. 50 indexed citations

13.

Giordano, Guido, Davide Melisi, Michèle Milella, et al.. (2014). Activity, Efficacy and Safety of Nab-Paclitaxel (Nab-P) and Gemcitabine (G) in Advanced Pancreatic Cancer (Apdac) Elderly Patients. Annals of Oncology. 25. iv242–iv242. 1 indexed citations

14.

Galetta, Domenico, Salvatore Pisconti, Saverio Cinieri, et al.. (2011). Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE). Clinical Lung Cancer. 12(6). 402–406. 9 indexed citations

15.

Pancione, Massimo, Nicola Forte, Alessandra Fucci, et al.. (2010). Prognostic role of β-catenin and p53 expression in the metastatic progression of sporadic colorectal cancer. Human Pathology. 41(6). 867–876. 28 indexed citations

16.

Ciccodicola, Alfredo, Lina Sabatino, Amelia Casamassimi, et al.. (2010). A novel germline mutation in Peroxisome Proliferator-Activated Receptor γ gene associated with large intestine polyp formation and dyslipidemia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1802(6). 572–581. 19 indexed citations

17.

Pignata, Sandro, Giovanni Scambia, Carmela Pisano, et al.. (2007). A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. British Journal of Cancer. 96(11). 1639–1643. 23 indexed citations

18.

Pignata, Sandro, Sabino De Placido, R. Biamonte, et al.. (2006). Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer. 6(1). 5–5. 99 indexed citations

19.

Sabatino, Lina, Amelia Casamassimi, Gianfranco Peluso, et al.. (2005). A Novel Peroxisome Proliferator-activated Receptor γ Isoform with Dominant Negative Activity Generated by Alternative Splicing. Journal of Biological Chemistry. 280(28). 26517–26525. 50 indexed citations

20.

Bertelli, Gianfilippo, Ornella Garrone, Marcella Occelli, et al.. (2005). Maintenance Hormone Therapy with Letrozole after First-Line Chemotherapy for Advanced Breast Cancer. Oncology. 68(4-6). 364–370. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact